Table 1.

Baseline patient and disease characteristics

Variable, n (%)Participants (N = 67)
Age group
 <65 years29 (43.3)
 ≥65 years38 (56.7)
Sex
 Male46 (68.7)
 Female21 (31.3)
WHO performance status
 020 (29.9)
 136 (53.7)
 210 (14.9)
 Missing1 (1.5)
Bellmunt criteriaa
 Risk group 012 (17.9)
 Risk group 127 (40.3)
 Risk group 225 (37.3)
 Risk group 33 (4.5)
Visceral disease
 Lung41 (61.2)
 Liver25 (37.3)
Lymph node metastases
 Yes19 (28.4)
 No46 (68.7)
 Missing2 (3)
Bony metastases
 Yes25 (37.3)
 No40 (59.7)
 Missing2 (3)
Prior immunotherapy at last medication11 (16.4)
FGFR3 status
 Not mutated0
 Mutatedb67 (100)
 Exon 7 R248C11 (16.4)
 Exon 7 S249C38 (56.7)
 Exon 10 Y375C3 (4.5)
 Exon 15 K652E/Q0
 Otherb15 (22.4)
  • Abbreviation: WHO, World Health Organization.

  • aPatients who had none of the following risk factors were in risk group 1: 1, hemoglobin level <100 g/L; 2, Eastern Cooperative Oncology Group performance status ≥1; 3, presence of liver metastases. Patients who had one, two, or three risk factors were placed in risk groups 1, 2, or 3, respectively.

  • bIncludes 5 patients with FGFR3–TACC3 fusion, rearrangement.